Grant: CIHR Fellowship
Direct Payment
$100,000.00
Timing of antiretroviral therapy initiation during pregnancy and child growth and neurodevelopment: quantifying consequences and understanding mechanisms.
EF 2019-20
Résumé
The 2015 World Health Organization guidelines recommend all pregnant women who are positive for human immunodeficiency virus (HIV) to initiate lifelong triple-drug antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV and to improve maternal survival. While it is essential that HIV-positive pregnant women begin ART as soon as possible after learning about their diagnosis, recent evidence from multiple studies suggests that women who begin ART before pregnancy may have a higher risk of having babies that are born too soon (preterm birth) or too small (low birthweight). Such adverse birth outcomes can put these babies at a higher risk of poor physical growth and brain development in early life, which may have a lasting impact throughout the lifespan. Yet, no study has previously evaluated the direct impact of timing of ART initiation during pregnancy on child growth and neurodevelopment. To address this gap, the purpose of this research is: 1) to examine the role of timing of ART initiation on child growth and neurodevelopment in the first year of life; 2) to quantify the role of poor birth outcomes, as mediators, in the pathway between timing of ART initiation and infant growth and neurodevelopment; and 3) to investigate whether some subgroups of women have a higher risk than others (e.g. based on HIV disease stage or maternal nutritional status). To address these objectives, data from a recently completed longitudinal study of 2300 HIV-positive pregnant women in Tanzania will be used. In this study, 50% of women started ART before pregnancy and 50% at variable times during the second trimester of pregnancy. Using advanced epidemiologic methods in causal inference, which overcome common pitfalls of conventional statistical techniques, this research will provide new evidence to understand the potential unintended consequences of ART, and ways in which treatment of HIV during pregnancy may be optimized to ensure all children survive and thrive.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
413065
Name
Perumal Nandita
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Timing of antiretroviral therapy initiation during pregnancy and child growth and neurodevelopment: quantifying consequences and understanding mechanisms.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antiretroviral Therapy (Art); Causal Inference; Child Growth; Child Neurodevelopment; Human Immunodeficiency Virus (Hiv); Perinatal And Pediatric Epidemiology; Pregnancy Outcomes
Abstract
The 2015 World Health Organization guidelines recommend all pregnant women who are positive for human immunodeficiency virus (HIV) to initiate lifelong triple-drug antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV and to improve maternal survival. While it is essential that HIV-positive pregnant women begin ART as soon as possible after learning about their diagnosis, recent evidence from multiple studies suggests that women who begin ART before pregnancy may have a higher risk of having babies that are born too soon (preterm birth) or too small (low birthweight). Such adverse birth outcomes can put these babies at a higher risk of poor physical growth and brain development in early life, which may have a lasting impact throughout the lifespan. Yet, no study has previously evaluated the direct impact of timing of ART initiation during pregnancy on child growth and neurodevelopment. To address this gap, the purpose of this research is: 1) to examine the role of timing of ART initiation on child growth and neurodevelopment in the first year of life; 2) to quantify the role of poor birth outcomes, as mediators, in the pathway between timing of ART initiation and infant growth and neurodevelopment; and 3) to investigate whether some subgroups of women have a higher risk than others (e.g. based on HIV disease stage or maternal nutritional status). To address these objectives, data from a recently completed longitudinal study of 2300 HIV-positive pregnant women in Tanzania will be used. In this study, 50% of women started ART before pregnancy and 50% at variable times during the second trimester of pregnancy. Using advanced epidemiologic methods in causal inference, which overcome common pitfalls of conventional statistical techniques, this research will provide new evidence to understand the potential unintended consequences of ART, and ways in which treatment of HIV during pregnancy may be optimized to ensure all children survive and thrive.
Competitiondate
201910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Perumal, Nandita
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~